ArticleTranslational cancer research2026
Magnetic resonance imaging-based radiomics for predicting P53-mutated hepatocellular carcinoma: intratumoral and peritumoral analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, and TP53 mutation acts as a trunk mutation driving tumor progression. However, TP53 mutation status can currently be determined only by invasive liver biopsy. This study applies multiregional radiomics features from magnetic resonance imaging (MRI) to predict P53-mutated HCC and offers a non-invasive tool for identifying this invasive subtype. Methods: In this retrospective study, data from 320 patients who underwent preoperative MRI were analyzed and divided into a training cohort (TC; n=224) and a validation cohort (VC; n=96). Clinical risk factors were identified using stepwise regression to construct predictive models. We evaluated three machine learningclassifiers across six MRI sequences, and the least absolute shrinkage and selection operator method was applied to select the best IntraPeri fusion model from four regions (whole tumor, IntraPeri_9mm, IntraPeri_11mm, and IntraPeri_13mm) to establish a radiomics model. The predictive nomogram for P53-mutated HCC integrated these clinical predictors with discriminative radiomics features, and its performance was assessed using receiver operating characteristic analysis, calibration, and decision curves. Results: Among 320 patients (259 men and 61 women; mean age, 58.25±11.51 years), 183 had P53-mutated HCC and 137 had non-P53-mutated HCC. The largest tumor diameter (LTD), Edmondson-Steiner grade, and rim arterial phase hyperenhancement were identified as independent predictors of P53-mutated HCC. The ExtraTrees classifier based on radiomics features from the optimal MRI sequence [T1-weighted imaging-arterial phase (T1WI-AP)] within the IntraPeri_11mm region achieved strong predictive accuracy [area under the curve (AUC) Conclusions: Nomogram combining clinical model with IntraPeri_11mm radiomics may serve as effective predictors of preoperative P53 mutation status in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.